Literature DB >> 16567921

Hypereosinophilic syndrome.

C Venkatesh1, E Mahender, S Janani, S Malathi, M Vijayakumar, B R Nammalwar.   

Abstract

Hypereosinophilic syndrome is a leukoproliferative disease characterised by sustained overproduction of eosinophils. The three diagnostic criteria for this disorder are (1) Eosinophilia of greater than 1500 cells/ml, persisting for longer than 6 months, (2) lack of another diagnosis to explain the eosinophilia and (3) signs and symptoms of organ involvement. We report a 15-year-old boy who was diagnosed as Hypereosinophilic syndrome based on these criteria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16567921     DOI: 10.1007/BF02825491

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   5.319


  9 in total

1.  Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome.

Authors:  E Juvonen; L Volin; A Koponen; T Ruutu
Journal:  Bone Marrow Transplant       Date:  2002-03       Impact factor: 5.483

Review 2.  The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.

Authors:  M J Chusid; D C Dale; B C West; S M Wolff
Journal:  Medicine (Baltimore)       Date:  1975-01       Impact factor: 1.889

3.  A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations.

Authors:  R T Schooley; M A Flaum; H R Gralnick; A S Fauci
Journal:  Blood       Date:  1981-11       Impact factor: 22.113

4.  Tubulointerstitial nephritis in a patient with eosinophilic fasciitis and IgA nephropathy.

Authors:  S Takeda; E Takazakura; Y Fukui
Journal:  Nephron       Date:  1995       Impact factor: 2.847

5.  The idiopathic hypereosinophilic syndrome.

Authors:  M A Alfaham; S D Ferguson; B Sihra; J Davies
Journal:  Arch Dis Child       Date:  1987-06       Impact factor: 3.791

6.  Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.

Authors:  Amy D Klion; Melissa A Law; Pierre Noel; Yae-Jean Kim; Thomas P Haverty; Thomas B Nutman
Journal:  Blood       Date:  2003-12-24       Impact factor: 22.113

Review 7.  Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome.

Authors:  B J Bain
Journal:  Br J Haematol       Date:  1996-10       Impact factor: 6.998

8.  Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.

Authors:  Amy D Klion; Jamie Robyn; Cem Akin; Pierre Noel; Margaret Brown; Melissa Law; Dean D Metcalfe; Cynthia Dunbar; Thomas B Nutman
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

9.  The idiopathic hypereosinophilic syndrome: clinical presentation, pathogenesis and therapeutic strategies.

Authors:  F Roufosse; E Bartholomé; L Schandené; M Goldman; E Cogan
Journal:  Drugs Today (Barc)       Date:  1998-04       Impact factor: 2.245

  9 in total
  1 in total

1.  Chronic eosinophilic leukemia: a case report and review of literature.

Authors:  Ashutosh Kumar; Swasti Sinha; Anil Kumar Tripathi
Journal:  Indian J Hematol Blood Transfus       Date:  2008-03-19       Impact factor: 0.900

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.